Senescent cardiomyocytes contribute to cardiac dysfunction following myocardial infarction
Aging Pathobiol Ther , 2020, 2(1): 58-61
In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with Competitive Advantage in Oncology," Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases
A pilot metabolic study demonstrated that a 750 mg NAD+ IV infusion over 6 hours was welltolerated in humans, with rapid metabolic clearance and no acute toxicity [10]
BPC-157 is not a controlled substance and is unlikely to be detected on a standard workplace drug test, which typically screens for common drugs of abuse